Phaseline

Companies › Satellos Bioscience

Satellos Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SAT-3247
AAK1 inhibitor that promotes functional rescue of asymmetric satellite cell division
AAK1Phase 2Duchenne Muscular DystrophyMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07287189SAT-3247Phase 2Duchenne Muscular DystrophyNeurologyMar 2027

From the company's SEC filings

Cash and short-term investments of $28m on 2025-12-31; operating cash outflow about $24m a year; runway about 14 months at that burn, to Mar 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

AAK1 (1)

Companies with the same targets

–

Companies built like this

Coya Therapeutics PepGen Cognition Therapeutics DiaMedica Therapeutics IGC Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.